PROTAGONIST THERAPEUTICS INC's ticker is PTGX and the CUSIP is 74366E102. A total of 153 filers reported holding PROTAGONIST THERAPEUTICS INC in Q4 2021. The put-call ratio across all filers is 0.62 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2022 | $1,333,977 | +38.0% | 122,271 | 0.0% | 0.05% | +31.6% |
| Q2 2022 | $967,000 | -66.6% | 122,271 | 0.0% | 0.04% | -62.7% |
| Q1 2022 | $2,895,000 | -16.2% | 122,271 | +21.0% | 0.10% | -8.1% |
| Q4 2021 | $3,455,000 | +126.1% | 101,037 | +17.2% | 0.11% | +126.5% |
| Q3 2021 | $1,528,000 | +4.0% | 86,237 | -28.9% | 0.05% | -18.3% |
| Q2 2019 | $1,469,000 | -34.1% | 121,341 | -31.6% | 0.06% | -34.1% |
| Q1 2019 | $2,230,000 | +68.0% | 177,425 | -10.0% | 0.09% | +59.6% |
| Q4 2018 | $1,327,000 | -41.1% | 197,138 | -10.0% | 0.06% | -30.5% |
| Q3 2018 | $2,254,000 | +53.1% | 219,042 | 0.0% | 0.08% | +46.4% |
| Q2 2018 | $1,472,000 | -21.8% | 219,042 | 0.0% | 0.06% | -23.3% |
| Q1 2018 | $1,882,000 | +9.2% | 219,042 | +164.5% | 0.07% | +10.6% |
| Q4 2017 | $1,723,000 | +1148.6% | 82,822 | +958.8% | 0.07% | +1220.0% |
| Q3 2017 | $138,000 | – | 7,822 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| JOHNSON & JOHNSON | 2,449,183 | $67,646,434 | 21.00% |
| COWEN AND COMPANY, LLC | 1,657,551 | $45,781,558 | 3.80% |
| Kynam Capital Management, LP | 975,298 | $26,937,731 | 3.70% |
| BVF INC/IL | 3,775,900 | $104,290,358 | 2.91% |
| RTW INVESTMENTS, LP | 5,415,514 | $149,576,497 | 2.85% |
| Cormorant Asset Management, LP | 1,500,000 | $41,430,000 | 2.32% |
| Ghost Tree Capital, LLC | 225,000 | $6,214,500 | 2.05% |
| 683 Capital Management, LLC | 814,000 | $22,482,680 | 1.62% |
| Perceptive Advisors | 1,469,761 | $40,594,799 | 1.18% |
| Artia Global Partners LP | 112,340 | $3,102,831 | 1.07% |